Skip to main content

GHRH (1–44) vs Hexarelin

Both GHRH (1–44) and Hexarelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.

GHRH (1–44)

Evidence A

Growth Hormone Releasing Hormone, full sequence

The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.

View full GHRH (1–44) profile →

Hexarelin

Evidence B

Hexarelin (HEX)

The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.

View full Hexarelin profile →

Side-by-Side

AttributeGHRH (1–44)Hexarelin
Evidence GradeAB
FDA StatusFDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limitedNot FDA-approved — research compound (cardioprotective signals investigated)
Typical Dose1 mcg/kg IV (diagnostic test)100 mcg, 1–2 times daily (subcutaneous)
Clinics Indexed2241
Categoriesgrowth-hormonegrowth-hormone, recovery

Key reported benefits — GHRH (1–44)

  • Endogenous GH stimulation
  • Diagnostic GH testing

Key reported benefits — Hexarelin

  • Strongest GH spike of GHRPs
  • Cardioprotective signals
  • Recovery

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons